LL-37 safety: route and formulation belong in the first question

“Is LL-37 safe?” is incomplete without naming the preparation, route, exposure and intended use. Applying a studied formulation to a wound is different from injecting a product into tissue or using it systemically. A responsible evidence review keeps these routes separate and identifies what human safety information actually supports each claim.

What FDA currently identifies

FDA’s bulk-substance safety page, checked in November 2026, places cathelicidin LL-37 in its table of nominated-but-withdrawn substances. The entry identifies potential immunogenicity, peptide-impurity and active-ingredient-characterization concerns, with insufficient human safety information. Withdrawal of a nomination should not be described as approval or as a finding that these concerns have been resolved.

“Immunogenicity” concerns the possibility of an immune response to an administered preparation. “Characterization” concerns knowing what material is present. Neither term tells you the numerical chance of a reaction for a particular person. They identify questions that require evidence rather than reassurance based solely on the peptide’s occurrence in the body.

A safety statement needs a denominator

Ask how many people received the exact formulation, for how long and through which route. Ask what adverse effects were actively sought and how long participants were followed. A small, short study can provide useful observations while leaving uncommon or delayed effects unresolved. “No signal detected” should not become “no risk exists.”

The HEAL LL-37 trial provides topical tolerability observations in a venous-ulcer protocol, but its efficacy result was negative across the full cohort. Its safety experience does not establish the safety of an unrelated injectable preparation. Keeping those two conclusions separate avoids using an encouraging safety description to imply a treatment benefit the trial did not demonstrate.

Human injection research needs its own context

There is also a small registered intratumoral melanoma study. It concerns injections into tumors in a research setting, not a general systemic wellness regimen. It would therefore be inaccurate to say that every human LL-37 study has been topical. It would be equally inaccurate to use the existence of that study as broad injectable safety validation.

Product questions worth documenting

• What is the exact peptide identity and finished formulation?
• Which human evidence matches the proposed route and clinical purpose?
• What uncertainty remains about adverse effects and longer exposure?
• Who is responsible for prescribing, dispensing and responding to problems?
• What current regulatory document supports any claimed access pathway?

A certificate describing a raw ingredient answers only the tests within its scope. It is not a substitute for human safety evidence about the finished preparation. Similarly, a prescription requirement does not establish FDA approval. FDA’s compounded-drug overview explains that compounded preparations do not undergo its premarket review for safety, effectiveness or quality.

Keep a dated evidence record

Save the exact product description and the date of the regulatory check. Revisit claims if the formulation, route or authoritative record changes. This approach avoids two opposite mistakes: treating uncertainty as proof of harm, or treating the absence of complete information as reassurance. The useful conclusion is specific about the evidence available and honest about what it cannot establish.